GSK Has High Hopes For COPD Vaccine
Phase II Data This Year
By combining its expertise in respiratory and vaccines, the UK drugs giant could have a potential blockbuster for chronic obstructive pulmonary disease, which is expected to become the third leading cause of death worldwide by the end of the decade.
You may also be interested in...
With CEO Emma Walmsley determined to keep investing in new technologies, GlaxoSmithKline has launched a two-year program to prepare for the separation of its pharma and consumer healthcare units into two companies.
Hot on the heels of winning EU fast-track review status for belantamab mafodotin, GlaxoSmithKline has asked the European Medicines Agency to grant accelerated assessment to another of its planned marketing applications.
GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.